MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- DIVIS LABORATORIES (pharmaceuticals)
- DIVIS LABORATORIES Financial Data
DIVIS LABORATORIES Fact Sheet 
(DIVI)
Potential 33x Opportunity: 3 Next-Generation Defence Stocks
Here is the latest financial fact sheet of DIVIS LABORATORIES. For more details, see the DIVIS LABORATORIES quarterly results and DIVIS LABORATORIES share price. For a sector overview, read our pharmaceuticals sector report.
DIVIS LABORATORIES Price History
| 1 Day | % | -1.3 |
| No. of shares | m | 265.47 |
| 1 Week | % | -6.4 |
| 1 Month | % | -1.1 |
| 1 Year | % | -24.8 |
| 52 week H/L | Rs | 5,425.0/3,365.1 |
DIVIS LABORATORIES Financials
| No. of Mths Year Ending |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
5-Yr Chart Click to enlarge
|
|---|
| DIVIS LABORATORIES EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,142 | 1,767 | 2,258 | 3,913 | 5,425 | |
| Low | Rs | 533 | 995 | 1,467 | 1,824 | 3,562 | |
| Sales per share (Unadj.) | Rs | 145.8 | 186.3 | 203.2 | 262.5 | 337.5 | |
| Earnings per share (Unadj.) | Rs | 33.0 | 51.0 | 51.9 | 74.7 | 111.5 | |
| Diluted earnings per share | Rs | 33.0 | 51.0 | 51.9 | 74.7 | 111.5 | |
| Cash flow per share (Unadj.) | Rs | 38.4 | 57.3 | 58.9 | 84.4 | 123.3 | |
| Dividends per share (Unadj.) | Rs | 10.00 | 16.00 | 16.00 | 20.00 | 30.00 | |
| Adj. dividends per share | Rs | 10.00 | 16.00 | 16.00 | 20.00 | 30.00 | |
| Avg Dividend yield | % | 1.2 | 1.2 | 0.9 | 0.7 | 0.7 | |
| Book value per share (Unadj.) | Rs | 223.2 | 262.1 | 275.4 | 350.1 | 441.8 | |
| Adj. book value per share | Rs | 223.2 | 262.1 | 275.4 | 350.1 | 441.8 | |
| Shares outstanding (eoy) | m | 265.47 | 265.47 | 265.47 | 265.47 | 265.47 | |
| Price / Sales ratio | x | 5.7 | 7.4 | 9.2 | 10.9 | 13.3 | |
| Avg P/E ratio | x | 25.3 | 27.1 | 35.9 | 38.4 | 40.3 | |
| P/CF ratio (eoy) | x | 21.8 | 24.1 | 31.6 | 34.0 | 36.5 | |
| Price / Book Value ratio | x | 3.8 | 5.3 | 6.8 | 8.2 | 10.2 | |
| Dividend payout | % | 30.3 | 31.4 | 30.9 | 26.8 | 26.9 | |
| Avg Mkt Cap | Rs m | 222,310 | 366,619 | 494,429 | 761,517 | 1,192,890 | |
| Total wages/salary | Rs m | 4,561 | 5,423 | 6,211 | 8,258 | 9,462 | |
| DIVIS LABORATORIES INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 38,702 | 49,463 | 53,944 | 69,694 | 89,598 | |
| Other income | Rs m | 1,134 | 1,556 | 1,896 | 627 | 1,159 | |
| Total revenues | Rs m | 39,836 | 51,019 | 55,841 | 70,321 | 90,757 | |
| Gross profit | Rs m | 12,628 | 18,730 | 18,232 | 28,611 | 38,811 | |
| Depreciation | Rs m | 1,425 | 1,689 | 1,862 | 2,556 | 3,115 | |
| Interest | Rs m | 24 | 47 | 71 | 21 | 20 | |
| Profit before tax | Rs m | 12,313 | 18,551 | 18,195 | 26,660 | 36,835 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 3,543 | 5,023 | 4,429 | 6,818 | 7,231 | |
| Profit after tax | Rs m | 8,770 | 13,527 | 13,765 | 19,843 | 29,605 | |
| Gross profit margin | % | 32.6 | 37.9 | 33.8 | 41.1 | 43.3 | |
| Effective tax rate | % | 28.8 | 27.1 | 24.3 | 25.6 | 19.6 | |
| Net profit margin | % | 22.7 | 27.3 | 25.5 | 28.5 | 33.0 | |
| DIVIS LABORATORIES BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 45,351 | 46,501 | 55,735 | 67,906 | 96,104 | |
| Current liabilities | Rs m | 6,534 | 8,468 | 18,205 | 17,284 | 24,544 | |
| Net working cap to sales | % | 100.3 | 76.9 | 69.6 | 72.6 | 79.9 | |
| Current ratio | x | 6.9 | 5.5 | 3.1 | 3.9 | 3.9 | |
| Inventory Days | Days | 338 | 219 | 76 | 10 | 9 | |
| Debtors Days | Days | 957 | 858 | 956 | 878 | 987 | |
| Net fixed assets | Rs m | 38,120 | 41,452 | 38,515 | 45,963 | 50,087 | |
| Share capital | Rs m | 531 | 531 | 531 | 531 | 531 | |
| "Free" reserves | Rs m | 58,717 | 69,041 | 72,568 | 92,415 | 116,751 | |
| Net worth | Rs m | 59,248 | 69,572 | 73,099 | 92,946 | 117,282 | |
| Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Total assets | Rs m | 83,471 | 87,953 | 94,250 | 113,869 | 146,191 | |
| Interest coverage | x | 520.5 | 397.4 | 255.8 | 1,270.5 | 1,842.8 | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | |
| Return on assets | % | 10.5 | 15.4 | 14.7 | 17.4 | 20.3 | |
| Return on equity | % | 14.8 | 19.4 | 18.8 | 21.3 | 25.2 | |
| Return on capital | % | 20.8 | 26.7 | 25.0 | 28.7 | 31.4 | |
| Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
| Imports to sales | % | 21.9 | 24.6 | 21.5 | 18.8 | 19.7 | |
| Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 8,485 | 12,187 | 11,597 | 13,127 | 17,676 | |
| Fx inflow | Rs m | 32,359 | 41,238 | 44,832 | 58,877 | 78,445 | |
| Fx outflow | Rs m | 9,042 | 12,405 | 11,837 | 13,341 | 17,953 | |
| Net fx | Rs m | 23,317 | 28,833 | 32,996 | 45,536 | 60,492 | |
| DIVIS LABORATORIES CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 7,759 | 9,543 | 12,159 | 19,469 | 19,118 | |
| From Investments | Rs m | -4,783 | -6,854 | -835 | 751 | -21,949 | |
| From Financial Activity | Rs m | -3,142 | -2,459 | -10,914 | -349 | -5,324 | |
| Net Cashflow | Rs m | -166 | 230 | 411 | 19,872 | -8,156 | |
Share Holding
Shareholding as on Jun 2022
|
Company Information
|
|||||||||||||||||||||||||||||||||||||
| CHM: Ramesh BV Nimmagadda | COMP SEC: M Satish Choudhury | YEAR OF INC: 1990 | BSE CODE: 532488 | FV (Rs): 2 | DIV YIELD (%): 0.8 |
Read: DIVIS LABORATORIES 2021-22 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: ZYDUS LIFESCIENCES LUPIN CIPLA AUROBINDO PHARMA SUN PHARMA
Compare DIVIS LABORATORIES With: ZYDUS LIFESCIENCES LUPIN CIPLA AUROBINDO PHARMA SUN PHARMA
Today's Market
Sensex Tanks 652 Points, Nifty Ends Below 17,800; IndusInd Bank & Bajaj Finserv Top Losers(Closing)
After opening the day on a flat note, Indian share markets turned volatile during the afternoon session and fell hard as selling was seen in banking and auto stocks.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.